Radiomic Analysis of Pharmacokinetic Heterogeneity Within Tumor Based on the Unsupervised Decomposition of Dynamic Contrast-Enhanced MRI for Predicting Histological Characteristics of Breast Cancer

J Magn Reson Imaging. 2022 Jun;55(6):1636-1647. doi: 10.1002/jmri.27993. Epub 2021 Nov 13.

Abstract

Background: Breast tumor heterogeneity is associated with histological characteristics. However, pharmacokinetic (PK) heterogeneity within tumor might merit further exploration.

Purpose: To enhance the predictive power of molecular subtypes, Ki-67, and tumor grade by analyzing PK heterogeneity within tumor based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).

Study type: Retrospective.

Population: Two hundred and eight biopsy-proven breast cancer patients, randomly divided into a training cohort (N = 144) and a testing cohort (N = 64).

Field strength/sequence: T1 -weighted DCE-MRI at 3.0 T.

Assessment: A convex analysis of mixtures-compartmental modeling decomposition method was used to estimate the PK parameter (i.e., the volume transfer constant Ktrans ) in tumor subregions with distinct physiological kinetic patterns, including fast-flow kinetics, slow-flow kinetics, and plasma input. Radiomic features based on the PK parameter were calculated from each tumor subregion.

Statistical tests: The training cohort was used to build random forest classifiers based on the optimal features determined by the 5-fold cross-validation method. The performance was assessed on the testing cohort using the area under the receiver operating characteristic curve (AUC). The AUCs derived from the tumor subregion-based PK parameter were compared with those of the original images of the entire tumor using the DeLong test. A P-value of <0.05 was considered statistically significant.

Results: The tumor subregion-based PK parameter, which yielded the highest AUCs of 0.8782, 0.7568, 0.7019, 0.7963, 0.8080, and 0.7375 for luminal A, luminal B, basal-like, human epidermal growth factor receptor 2, Ki-67, and tumor grade, respectively, obtained better diagnostic performance than the original images in the entire tumor (highest AUCs = 0.8612, 0.6191, 0.5593, 0.7704, 0.7494, and 0.6261, respectively). In particular, statistically significant improvement in the diagnostic performance was obtained for luminal B.

Data conclusion: Radiomic analysis of PK heterogeneity within tumor can enhance the predictive performance of radiomic models compared with that of the entire tumor.

Level of evidence: 4 TECHNICAL EFFICACY STAGE: 3.

Keywords: compartmental modeling; convex analysis of mixtures; dynamic contrast-enhanced magnetic resonance imaging; pharmacokinetic heterogeneity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / diagnostic imaging
  • Breast Neoplasms* / pathology
  • Contrast Media / pharmacokinetics
  • Female
  • Humans
  • Ki-67 Antigen / metabolism
  • Magnetic Resonance Imaging / methods
  • ROC Curve
  • Retrospective Studies

Substances

  • Contrast Media
  • Ki-67 Antigen